EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC)

Roni Gillis iD, Tamar Zahavi, Nir Peled, Adar Yaacov, Basel Afifi, Jaber Salim, Reham Basheer, Noam Asna, Arnon Makori, Michael Peer, Evgeni Gershman, Yoav Manaster und 2 weitere

Cancers · 14.04.2026 · 18 (8) · 1246

DOI: 10.3390/cancers18081246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 14.04.2026. Verfasst von Roni Gillis und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Helmsley Cancer Center, The Eisenberg R&D Authority, Shaare Zedek Medical Center, 12 Shmuel Bait St., Jerusalem 9103102, Israel. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Minimal residual disease (MRD) assessment is an emerging tool for refining the risk of relapse following definitive therapy in non-small-cell lung cancer (NSCLC). However, data regarding its clinical impact on the decision-making process remain limited. We evaluated MRD feasibility and its impact in the real-world setting.

Methods

A pooled retrospective analysis of longitudinal MRD data in NSCLC patients (n = 34: Signatera™ (Exome), n = 25, Guardant Reveal™, n = 9) was implemented. Co-primary endpoints: MRD feasibility and clinical impact on management (changes in surveillance intensity or therapy escalation/de-escalation). Secondary endpoints: sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy for recurrence detection, and MRD lead time.

Results

MRD was feasible in 32/34 patients (94.1%); longitudinal testing included two samples in 15 patients (44.1%) and three samples in 2 patients (5.9%). Signatera™ (Exome) failed in 2/25 (8.0%) due to insufficient tissue. MRD influenced management in 20/34 (58.8%) patients, most commonly supporting therapy de-escalation (15/34, 44.1%), followed by imaging surveillance modification (3/34, 8.8%) and therapy escalation (2/34, 5.9%). In univariable analysis, tumor grade and STAS were associated with MRD-driven management impact, but neither remained significant in multivariable analysis. With a median follow-up of 18.9 months (IQR 8.5–30.7), MRD was positive in 6/32 (18.8%), while recurrence/progression occurred in 10/32 (31.3%) patients. MRD yielded 21 true negatives, five true positives, five false negatives (including two isolated brain recurrences), and one false positive, corresponding to a sensitivity of 50.0%, specificity of 95.5%, PPV of 83.3%, NPV of 80.8%, and an accuracy of 81.3%. The median MRD lead time (n = 5) was 1.31 months (range, 0.46–5.52).

Conclusions

In this real-world cohort, MRD testing was feasible and frequently guided clinical decisions, mainly supporting treatment de-escalation. MRD was highly specific but less sensitive. Prospective studies are needed to define optimal testing intervals and validate MRD-guided strategies.

Schlagwörter

Stichwörter der Autor:innen

circulating tumor DNA (ctDNA)clinical impactliquid biopsylung cancerminimal residual disease (MRD)treatment de-escalation

Autor:innen und Institutionen

  • The Helmsley Cancer Center, The Eisenberg R&D Authority, Shaare Zedek Medical Center, 12 Shmuel Bait St., Jerusalem 9103102, Israel.
  • Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190500, Israel.
  • ProGenetics, 2 HaMatzuda St., Azor 5800146, Israel.
  • Imaging Services, Assuta Medical Centers, 20 HaBarzel St., Ramat HaHayal, Tel Aviv 6971028, Israel.
  • Department of Thoracic Surgery, Tel Aviv Medical Center, 6 Weizmann St., Tel Aviv 6423906, Israel.
  • Faculty of Medicine, Tel-Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel.

ORCID-Profile: Roni Gillis, Elizabeth Dudnik

Zitieren

APA

Gillis, R., Zahavi, T., Peled, N., Yaacov, A., Afifi, B., Salim, J., Basheer, R., Asna, N., Makori, A., Peer, M., Gershman, E., Manaster, Y., Moreh Rahav, O., & Dudnik, E. (2026). The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC). Cancers, 18(8), 1246. https://doi.org/10.3390/cancers18081246

Vancouver

Gillis R, Zahavi T, Peled N, Yaacov A, Afifi B, Salim J, et al. The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC). Cancers. 2026;18(8):1246. doi:10.3390/cancers18081246

BibTeX
@article{Gillis2026,
  author = {Gillis, Roni and Zahavi, Tamar and Peled, Nir and Yaacov, Adar and Afifi, Basel and Salim, Jaber and Basheer, Reham and Asna, Noam and Makori, Arnon and Peer, Michael and Gershman, Evgeni and Manaster, Yoav and Moreh Rahav, Osnat and Dudnik, Elizabeth},
  title = {The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC)},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1246},
  doi = {10.3390/cancers18081246}
}
Kostenlos starten →